Therapeutic Potential of ⁴⁷Sc in Comparison to ¹⁷⁷Lu and ⁹⁰Y: Preclinical Investigations

Targeted radionuclide therapy with ¹⁷⁷Lu- and ⁹⁰Y-labeled radioconjugates is a clinically-established treatment modality for metastasized cancer. ⁴⁷Sc is a therapeutic radionuclide that decays with a half-life of 3.35 days and emits medium-energy &#946;<sup>&#8722;</...

全面介紹

書目詳細資料

Principais autores:	Klaudia Siwowska, Patrycja Guzik, Katharina A. Domnanich, Josep M. Monné Rodríguez, Peter Bernhardt, Bernard Ponsard, Roger Hasler, Francesca Borgna, Roger Schibli, Ulli Köster, Nicholas P. van der Meulen, Cristina Müller
格式:	Artigo
語言:	Inglês
出版:	MDPI AG 2019-08-01
叢編:	Pharmaceutics
主題:	<sup>47</sup>Sc <sup>177</sup>Lu <sup>90</sup>Y radionuclide therapy SPECT folate receptor DOTA-folate IGROV-1 tumor xenografts preclinical therapy
在線閱讀:	https://www.mdpi.com/1999-4923/11/8/424
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!